MAG Silver Reports First Quarter Financial Results financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
About AEX AEX s principal business objectives are the identification, acquisition, exploration and development of gold properties in Greenland. The Corporation s principal asset is a 100% interest in the Nalunaq Project, an advanced exploration stage property with an exploitation license including the previously operating Nalunaq gold mine. The Corporation has a portfolio of gold assets covering 3,870km
2, the largest portfolio of gold assets in Southern Greenland covering the two known gold belts in the region. AEX is incorporated under the Canada Business Corporations Act and wholly owns Nalunaq A/S, incorporated under the Greenland Public Companies Act. Forward-Looking Information This press release contains forward-looking information within the meaning of applicable securities legislation, which reflects the Corporation s current expectations regarding future events and the future growth of the Corporation s business. In this press release there is fo
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023
Clinical development plans on schedule in both hematological and solid tumor programs
Leadership strengthened through key management and board appointments
UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers (bsTCEs) to transform cancer therapy, today reported its business update and first quarter 2021 financial results.
“We continue to make important strides across all aspects of our business as we transition to a clinical stage organization,” said Stephen Hurly, chief executive officer of LAVA Therapeutics. “With the recent additions to our leadership team and board and the proceeds from
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results GlobeNewswire May 20, 2021 IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics.